Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2– advanced breast cancer in postmenopausal women: analysis from a Medicare perspective
Ribociclib improved health outcomes with a minimal relative cost increase and is therefore a highly cost-effective 1 L treatment option vs. palbociclib in patients with HR+/HER2- aBC from the Medicare perspective.
Authors
- Thomas E. Delea (ORCID: https://orcid.org/0000-0001-5493-1925)
- Sarah Sammons (ORCID: https://orcid.org/0000-0003-2589-9422)
- Purnima Pathak (ORCID: https://orcid.org/0000-0002-6225-9128)
- Vijayakrishna K. Gadi (ORCID: https://orcid.org/0000-0002-5427-7465)
- Paolo Tarantino (ORCID: https://orcid.org/0000-0001-8686-0228)
- Daniel Stellato
- Gary Sopher
Institutions
- Novartis (Switzerland) (CH)
- University of Illinois Chicago (US)
- Prevea Health (US)
- Translational Research in Oncology (FR)
- Dana-Farber Cancer Institute (US)
- Novartis (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1080/13696998.2025.2594952
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00